| Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma (NCT00723359) | Biotest Pharmaceuticals Corporation | 2008-08-01 |
| Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy (NCT00691704) | Cristina Gasparetto | 2008-08-01 |
| Natural Killer Cells and Bortezomib to Treat Cancer (NCT00720785) | National Heart, Lung, and Blood Institute (NHLBI) | 2008-08-01 |
| Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT (NCT00709592) | Virginia Commonwealth University | 2008-07-21 |
| Study of MLN8237 in Participants With Advanced Hematological Malignancies (NCT00697346) | Millennium Pharmaceuticals, Inc. | 2008-07-11 |
| A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma (NCT00718419) | Eli Lilly and Company | 2008-07-01 |
| UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma (NCT00734877) | University of Arkansas | 2008-07-01 |
| A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma (NCT00722566) | Millennium Pharmaceuticals, Inc. | 2008-07-01 |
| Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma (NCT00743288) | Oncotherapeutics | 2008-07-01 |
| Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma (NCT00718601) | Geron Corporation | 2008-07-01 |
| A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib (NCT00706953) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2008-07-01 |
| Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies (NCT00714259) | University of Alabama at Birmingham | 2008-07-01 |
| Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) in Multiple Myeloma (NCT01829412) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2008-07-01 |
| A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT) (NCT00985959) | Janssen Pharmaceutical K.K. | 2008-07-01 |
| Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients (NCT01160107) | Fondazione EMN Italy Onlus | 2008-07-01 |
| Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM (NCT00648739) | Alexion Pharmaceuticals, Inc. | 2008-06-19 |
| Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis (NCT00790647) | Boston Medical Center | 2008-06-01 |
| Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma (NCT00722488) | Millennium Pharmaceuticals, Inc. | 2008-06-01 |
| European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy (NCT00700531) | University Hospital Birmingham | 2008-06-01 |
| MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma (NCT00833833) | Celgene Corporation | 2008-06-01 |
| RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma (NCT00729638) | Massachusetts General Hospital | 2008-06-01 |
| Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy (NCT01314963) | Stanford University | 2008-06-01 |
| Inflammatory Cytokines in Symptom Production in Multiple Myeloma (NCT00688168) | M.D. Anderson Cancer Center | 2008-05-09 |
| Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis (NCT00679367) | Boston Medical Center | 2008-05-01 |
| Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma (NCT00724568) | University of Michigan Rogel Cancer Center | 2008-05-01 |
| Dasatinib in Combination With Revlimid (and Dexamethasone) (NCT00560391) | Bristol-Myers Squibb | 2008-05-01 |
| A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (NCT00664898) | Genentech, Inc. | 2008-05-01 |
| Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD (NCT00908232) | Janssen-Cilag International NV | 2008-05-01 |
| A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies. (NCT00726869) | Abbott | 2008-05-01 |
| Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma (NCT00609817) | La Jolla Pharmaceutical Company | 2008-05-01 |
| Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma. (NCT00532675) | Novartis Pharmaceuticals | 2008-04-22 |
| A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies (NCT01315132) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2008-04-10 |
| Prevention of Left Ventricular Dysfunction During Chemotherapy (NCT01110824) | Hospital Clinic of Barcelona | 2008-04-01 |
| Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma (NCT01207765) | Tufts Medical Center | 2008-04-01 |
| Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma (NCT00574288) | Janssen Research & Development, LLC | 2008-03-26 |
| A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib (NCT00689507) | Applied Molecular Evolution | 2008-03-01 |
| Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) (NCT00910897) | Intergroupe Francophone du Myelome | 2008-03-01 |
| NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma (NCT00667082) | Celgene | 2008-03-01 |
| Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. (NCT01026701) | Janssen Korea, Ltd., Korea | 2008-03-01 |
| ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain (NCT00656305) | InSightec | 2008-03-01 |
| Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden (NCT00651937) | M.D. Anderson Cancer Center | 2008-03-01 |
| Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma (NCT00560352) | Bristol-Myers Squibb | 2008-02-01 |
| Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen (NCT00615589) | University of Michigan Rogel Cancer Center | 2008-02-01 |
| Preemptive Strike With Bortezomib in Multiple Myeloma Patients (NCT00657553) | University of Arkansas | 2008-02-01 |
| Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment (NCT00670631) | Guido Tricot | 2008-02-01 |
| A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse (NCT00546780) | Bristol-Myers Squibb | 2008-02-01 |
| Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors (NCT00618969) | University of Arizona | 2008-02-01 |
| Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) (NCT00617591) | H. Lee Moffitt Cancer Center and Research Institute | 2008-01-01 |
| An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma. (NCT00555906) | Pfizer | 2008-01-01 |
| Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant (NCT00674427) | University of Pennsylvania | 2008-01-01 |
| Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy (NCT01094548) | Merck KGaA, Darmstadt, Germany | 2008-01-01 |
| Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma (NCT00538824) | Weill Medical College of Cornell University | 2007-12-01 |
| Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma (NCT00511082) | Otsuka Beijing Research Institute | 2007-12-01 |
| Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants (NCT00622505) | Novartis Pharmaceuticals | 2007-11-07 |
| Investigation of the Cylex® ImmuKnow® Assay (NCT00569842) | Indiana University | 2007-11-01 |
| MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning (NCT00564200) | PETHEMA Foundation | 2007-11-01 |
| Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients (NCT00536575) | SCRI Development Innovations, LLC | 2007-11-01 |
| Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). (NCT00665314) | Genzyme, a Sanofi Company | 2007-11-01 |
| Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma (NCT00594126) | Geron Corporation | 2007-11-01 |
| Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients (NCT00562224) | Pharmacyclics LLC. | 2007-11-01 |
| Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System (NCT00520130) | National Cancer Institute (NCI) | 2007-10-30 |
| Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty. (NCT00748631) | Assistance Publique - Hôpitaux de Paris | 2007-10-01 |
| Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma (NCT00538733) | Weill Medical College of Cornell University | 2007-10-01 |
| A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma (NCT00531453) | Millennium Pharmaceuticals, Inc. | 2007-10-01 |
| Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction (NCT00547365) | University of Tennessee | 2007-10-01 |
| Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma (NCT00540644) | Attaya Suvannasankha | 2007-10-01 |
| Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen (NCT00556452) | University of Michigan Rogel Cancer Center | 2007-10-01 |
| Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates (NCT00577642) | Massachusetts General Hospital | 2007-10-01 |
| An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function (NCT00718640) | Janssen-Ortho Inc., Canada | 2007-10-01 |
| Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma (NCT00602511) | Nordic Myeloma Study Group | 2007-10-01 |
| Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma (NCT00532389) | Novartis Pharmaceuticals | 2007-10-01 |
| Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma (NCT00531284) | Amgen | 2007-09-01 |
| Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma (NCT00530816) | Amgen | 2007-09-01 |
| An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) (NCT00608907) | Millennium Pharmaceuticals, Inc. | 2007-09-01 |
| Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation (NCT00461955) | University Hospital, Bordeaux | 2007-08-01 |
| Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma (NCT00525447) | Seagen Inc. | 2007-08-01 |
| A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma (NCT00514371) | Bristol-Myers Squibb | 2007-08-01 |
| Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients (NCT00507442) | Millennium Pharmaceuticals, Inc. | 2007-08-01 |
| Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma (NCT00511238) | Amgen | 2007-08-01 |
| T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer (NCT00602693) | Masonic Cancer Center, University of Minnesota | 2007-07-23 |
| Bortezomib and High-dose Melphalan at Myeloma Relapse (NCT00508209) | Nordic Myeloma Study Group | 2007-07-01 |
| Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma (NCT00555100) | Celgene | 2007-07-01 |
| Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors (NCT00701844) | University of North Carolina, Chapel Hill | 2007-07-01 |
| Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT) (NCT00642395) | University Hospital, Toulouse | 2007-07-01 |
| A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) (NCT00499239) | Gilead Sciences | 2007-07-01 |
| A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression (NCT00482261) | Peter MacCallum Cancer Centre, Australia | 2007-06-01 |
| Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone (NCT00507416) | Millennium Pharmaceuticals, Inc. | 2007-06-01 |
| Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) (NCT00579111) | Baylor College of Medicine | 2007-06-01 |
| Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma (NCT00482846) | Barbara Ann Karmanos Cancer Institute | 2007-06-01 |
| A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER) (NCT00473590) | Genentech, Inc. | 2007-06-01 |
| Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients (NCT00551928) | Fondazione EMN Italy Onlus | 2007-06-01 |
| An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma (NCT00552396) | Innate Pharma | 2007-05-01 |
| Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation (NCT00626626) | Milton S. Hershey Medical Center | 2007-05-01 |
| QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression (NCT00480363) | PETHEMA Foundation | 2007-05-01 |
| Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma (NCT01090921) | Boston VA Research Institute, Inc. | 2007-05-01 |
| Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma (NCT00483262) | Dana-Farber Cancer Institute | 2007-05-01 |
| Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma (NCT00445068) | Novartis Pharmaceuticals | 2007-04-16 |
| A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD) (NCT00577668) | University of Arkansas | 2007-04-01 |
| 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE (NCT00577512) | University of Arkansas | 2007-04-01 |
| A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma (NCT00464178) | Hackensack Meridian Health | 2007-04-01 |